212 related articles for article (PubMed ID: 32252479)
1. High-Capacity Adenoviral Vectors Permit Robust and Versatile Testing of
Brescia M; Janssen JM; Liu J; Gonçalves MAFV
Cells; 2020 Apr; 9(4):. PubMed ID: 32252479
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
[TBL] [Abstract][Full Text] [Related]
3. Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.
Maggio I; Stefanucci L; Janssen JM; Liu J; Chen X; Mouly V; Gonçalves MA
Nucleic Acids Res; 2016 Feb; 44(3):1449-70. PubMed ID: 26762977
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of viral vectors as vehicles for DMD gene editing.
Maggio I; Chen X; Gonçalves MA
Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Wong TWY; Cohn RD
Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
[TBL] [Abstract][Full Text] [Related]
6. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
[TBL] [Abstract][Full Text] [Related]
7. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
[TBL] [Abstract][Full Text] [Related]
8. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
[TBL] [Abstract][Full Text] [Related]
9. Selection-free precise gene repair using high-capacity adenovector delivery of advanced prime editing systems rescues dystrophin synthesis in DMD muscle cells.
Wang Q; Capelletti S; Liu J; Janssen JM; Gonçalves MAFV
Nucleic Acids Res; 2024 Mar; 52(5):2740-2757. PubMed ID: 38321963
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
Chemello F; Olson EN; Bassel-Duby R
Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
[TBL] [Abstract][Full Text] [Related]
11. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
Choi E; Koo T
Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
[TBL] [Abstract][Full Text] [Related]
12. Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components.
Maggio I; Zittersteijn HA; Wang Q; Liu J; Janssen JM; Ojeda IT; van der Maarel SM; Lankester AC; Hoeben RC; Gonçalves MAFV
Gene Ther; 2020 May; 27(5):209-225. PubMed ID: 31900423
[TBL] [Abstract][Full Text] [Related]
13. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells.
Gonçalves MA; Holkers M; Cudré-Mauroux C; van Nierop GP; Knaän-Shanzer S; van der Velde I; Valerio D; de Vries AA
Mol Ther; 2006 May; 13(5):976-86. PubMed ID: 16443396
[TBL] [Abstract][Full Text] [Related]
14. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
[TBL] [Abstract][Full Text] [Related]
15. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
[TBL] [Abstract][Full Text] [Related]
16. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
[TBL] [Abstract][Full Text] [Related]
17. Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.
Pini V; Mariot V; Dumonceaux J; Counsell J; O'Neill HC; Farmer S; Conti F; Muntoni F
Sci Rep; 2022 Mar; 12(1):3756. PubMed ID: 35260651
[TBL] [Abstract][Full Text] [Related]
18. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
[TBL] [Abstract][Full Text] [Related]
19. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
PLoS One; 2020; 15(1):e0228072. PubMed ID: 31961902
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells.
Maggio I; Holkers M; Liu J; Janssen JM; Chen X; Gonçalves MA
Sci Rep; 2014 May; 4():5105. PubMed ID: 24870050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]